Cargando…
Tonabersat Inhibits Connexin43 Hemichannel Opening and Inflammasome Activation in an In Vitro Retinal Epithelial Cell Model of Diabetic Retinopathy
This study was undertaken to evaluate the connexin hemichannel blocker tonabersat for the inhibition of inflammasome activation and use as a potential treatment for diabetic retinopathy. Human retinal pigment epithelial cells (ARPE-19) were stimulated with hyperglycemia and the inflammatory cytokine...
Autores principales: | Lyon, Heather, Shome, Avik, Rupenthal, Ilva D., Green, Colin R., Mugisho, Odunayo O. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7794685/ https://www.ncbi.nlm.nih.gov/pubmed/33396676 http://dx.doi.org/10.3390/ijms22010298 |
Ejemplares similares
-
Orally Delivered Connexin43 Hemichannel Blocker, Tonabersat, Inhibits Vascular Breakdown and Inflammasome Activation in a Mouse Model of Diabetic Retinopathy
por: Mugisho, Odunayo O., et al.
Publicado: (2023) -
Connexin therapeutics: blocking connexin hemichannel pores is distinct from blocking pannexin channels or gap junctions
por: Acosta, Monica L., et al.
Publicado: (2020) -
Immunohistochemical Characterization of Connexin43 Expression in a Mouse Model of Diabetic Retinopathy and in Human Donor Retinas
por: Mugisho, Odunayo O., et al.
Publicado: (2017) -
Xentry-Gap19 inhibits Connexin43 hemichannel opening especially during hypoxic injury
por: Coutinho, Frazer P., et al.
Publicado: (2020) -
Differential Action of Connexin Hemichannel and Pannexin Channel Therapeutics for Potential Treatment of Retinal Diseases
por: Mat Nor, Mohd N., et al.
Publicado: (2021)